Search

Your search keyword '"Christina Kemanetzi"' showing total 14 results
Start Over Author "Christina Kemanetzi" Topic dermatology
14 results on '"Christina Kemanetzi"'

1. The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention

Author

Christina Kemanetzi, Konstantinos Lallas, Elisavet Lazaridou, Chrysoula Papageorgiou, Aimilios Lallas, Alexandros Stratigos, Eleni Timotheadou, George Lazaridis, Dimitrios Dionysopoulos, Kalliopi Kalaitzi, Antonios Tsimpidakis, Myrto Trakatelli, Aikaterini Patsatsi, Vasiliki Nikolaou, and Zoe Apalla

Subjects
checkpoint inhibitors, skin toxicity, skin rash, quality of life, patient reported outcomes, Dermatology, RL1-803
Abstract

Introduction: Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs)and their course after dermatologic intervention are scarce. Objectives To assess the impact of dirAEs on patients' QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL. Methods We enrolled oncologic patients with dirAEs managed in two supportive oncodermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS). Results Overall, 110 patients were enrolled in the study. Mean(SD) DLQI and pNRS scores were 15.54 (5.44) and7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after1st intervention compared to baseline, and 2nd intervention compared to 1st [mean (SD) decrease 4.38 (2.91), p

Published
2024
Full Text
View/download PDF

2. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients With Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp

Author

Eirini Kyrmanidou, Christina Kemanetzi, Chatzopoulos Stavros, Myrto-Georgia Trakatelli, Aikaterini Patsatsi, Xenia Madia, Dimitra Ignatiadi, Evangelia Kalloniati, Zoe Apalla, and Elizabeth Lazaridou

Subjects
psoriasis, genital psoriasis, scalp psoriasis, secukinumab, Greece, Dermatology, RL1-803
Abstract

Introduction: Psoriasis is a chronic inflammatory disease with multiple skin manifestations, and in case of lesions affecting the genital area sexual health impairment and psychological distress can furthermore impair the quality of life of patients. Secukinumab is a fully humanized antagonist of IL-17A and is indicated for the treatment of moderate-to-severe psoriasis. Objectives: This study was conducted in order to gather retrospective real-world data regarding the efficacy of secukinumab in treating patients with moderate-to-severe plaque psoriasis in Greece. We included difficult-to-treat manifestations in our analysis, specifically regarding the efficacy in the genital area and on the skin folds. Methods: All adult patients receiving 300 mg of secukinumab and attending follow-up visits on a regular basis, according to routine medical practice, were included. The timeline of the study was from 2015 to 2020. Primary endpoint of the study was the percentage of patients who achieved a PASI75 response rate at week 16 and week 52 post baseline. Results: Ninety-nine patients were included in the study population. Regarding difficult-to-treat manifestations, we recorded scalp involvement in 74.74% (74/99) of our patients, genital psoriasis in 27.27% (27/99), and skin fold involvement (psoriasis inversa) in 17% (17/99). At week 16, PASI75/PASI90/PASI100 were observed in 87.5%/69.8%/49%, respectively. Treatment with secukinumab during the 208 weeks of observation did not reveal any major adverse event. Conclusion: According to our outcomes, secukinumab is an effective treatment choice for treating chronic plaque psoriasis, but additionally it can be efficacious in the subgroups of patients with difficult-to-treat manifestations.

Published
2024
Full Text
View/download PDF

3. Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients

Author

Anastasia Emvalomati, Valentina Oflidou, Chryssoula Papageorgiou, Christina Kemanetzi, Maria Giannouli, Evangelia Kalloniati, Konstantinos Efthymiadis, Chrysanthi Koukoutzeli, Eleni Timotheadou, Anastasia Trigoni, Aikaterini Patsastsi, Elizabeth Lazaridou, Zoe Apalla, and Myrto Trakatelli

Subjects
nail toxicity, nail changes, chemotherapy, targeted treatment, immune checkpoint inhibitors, Dermatology, RL1-803
Abstract

Introduction Nail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy. Objectives We aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management. Methods Retrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity. The was searched for relevant studies. Results A wide spectrum of nail toxicities is associated with both, conventional and newer anticancer agents. The frequency of nail involvement, especially with immunotherapy and new targeted agents remains unknown and patients with different cancer types receiving different regimens may develop the same nail disorder, whereas patients with the same type of cancer under the same chemotherapeutic treatment may develop different types of nail alterations. The underlying mechanisms of the varying individual susceptibility and the diverse nail responses to various anticancer treatments need further investigation. Conclusion Early recognition and treatment of nail toxicities can minimize their impact, allowing better adherence to conventional and newer oncologic treatments. Dermatologists, oncologists and other implicated physicians should be aware of these burdensome adverse effects in order to guide management and prevent impairment of patients’ quality of life.

Published
2023
Full Text
View/download PDF

4. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review

Author

Zoe Apalla, Chryssoula Papageorgiou, Aimilios Lallas, Florentina Delli, Christina Fotiadou, Christina Kemanetzi, and Elizabeth Lazaridou

Subjects
immune checkpoint inhibitors, skin toxicity, adverse effects, nivolumab, pembrolizumab, ipilimumab, Dermatology, RL1-803
Abstract

Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-like toxicities, named immune-related adverse events (irAEs). Dermatologic reactions are among the most prevalent irAE triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients’ quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs.

Published
2021
Full Text
View/download PDF

5. Solitary trichoepithelioma in an 8-year-old child: clinical, dermoscopic and histopathologic findings

Author

Elizabeth Lazaridou, Christina Fotiadou, Aikaterini Patsatsi, Eirini Kyrmanidou, Christina Kemanetzi, and Demetrios Ioannidis

Subjects
trichoepithelioma, basal cell carcinoma, diagnosis, dermoscopy, histopathology, Dermatology, RL1-803
Abstract

Solitary trichoepithelioma (TE) is a rare, benign tumor of follicular origin that in certain cases is difficult to differentiate from basal cell carcinoma (BCC). We report the case of an 8-year-old girl with a pale pink, soft lesion on the neck. The clinical image of the lesion was equivocal, while some dermoscopic findings—blue-gray globules and arborizing vessels—could not exclude the presence of BCC from the differential diagnosis, although that would have been a very unlikely case considering the age of the patient. The histopathologic examination established the diagnosis of TE. Given the occasion of this challenging case we try to list the key clinical, dermoscopic and histopathological characteristics of TE and BCC in order to elucidate the differential diagnosis of these two entities.

Published
2014
Full Text
View/download PDF

6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients

Author

Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria Echeverría, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud, Nikolaou, Vasiliki A, Apalla, Zoe, Carrera, Cristina, Fattore, Davide, Sollena, Pietro, Riganti, Julia, Segura, Sonia, Freites-Martinez, Azael, Lallas, Konstantino, Romano, Maria Concetta, Oikonomou, Chrysa, Starace, Michela, Dimopoulos, Meletios A, Kyrgidis, Athanassio, Lazaridou, Elizabeth, Giavedoni, Priscila, Annunziata, Maria Carmela, Peris, Ketty, Echeverría, Maria, Lopez-Tujillo, Emilio, Syrigos, Konstandino, Papageorgiou, Chryssoula, Podlipnik, Sebastian, Fabbrocini, Gabriella, Torre, Ana C, Kemanetzi, Christina, Villa-Crespo, Lorena, Lallas, Aimilio, Stratigos, Alexander J, and Sibaud, Vincent

Subjects
Psoriasi, Lung Neoplasms, Pruritus, Vitiligo, Pell--Càncer, immune checkpoint inhibitor, Dermatology, Exanthema, Dermatologia, Cohort Studies, Antineoplastic Agents, Immunological, Venereology, Carcinoma, Non-Small-Cell Lung, Neoplasms, Humans, Psoriasis, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Immune Checkpoint Inhibitors, Melanoma, Retrospective Studies
Abstract

Summary Background Cutaneous immune-related adverse events (irAEs) represent the most frequent toxicities induced by immune checkpoint inhibitors (ICIs). Objectives To investigate clinical associations of cutaneous toxicities induced by different ICI therapies. Methods This was a multicentre retrospective international cohort study of patients with cancer who developed cutaneous irAEs under ICI therapy. Analysis was performed of the rates and basic characteristics of all cutaneous toxicities, and identification of any associations was performed using univariate and multivariate models. Results In total, 762 patients were included, who developed 993 cutaneous toxicities. Forty different types of skin toxicities were identified. Psoriasis (175 patients, 23·0%) and pruritus (171 patients, 22·4%) were the most common toxicities, followed by macular rash (161 patients, 21·1%) and eczematous-type reactions (150 patients, 19·7%). Multivariate analysis showed that among patients with macular rash, vitiligo or multiple toxicities, patients received ICIs more frequently for melanoma than for NSCLC. Moreover, anti-CTLA4 was less frequent than anti-programmed death 1 treatment in patients with macular rash [odds ratio (OR) 0·11, 95% confidence interval (CI) 0·01–0·76] and vitiligo (OR 0·07, 95% CI 0·006–0·78). A significant association was also seen in patients treated with a combination of ICI and chemotherapy vs. ICI monotherapy. They less frequently developed psoriasis (OR 0·08, 95% CI 0·02–0·31), lichenoid reactions (OR 0·15, 95% CI 0·03–0·77) and eczematous reactions (OR 0·24, 95% CI 0·07–0·78), all compared with pruritic rash. Conclusions Our study showed that skin-oriented toxicities do not share a single pattern and are related to several factors, including the specific agent administered and the underlying malignancy treated. Follow-up plans should be individualized in order to minimize the risk for severe reactions that could compromise optimum therapeutic outcome. What is already known about this topic? Patients with cancer treated with different immune checkpoint inhibitors (ICIs) carry an increased risk of developing various types of skin toxicities. What are the clinical implications of this work? In this multicentre cohort study we showed that ICI-related skin toxicities do not share a single pattern and may depend on several factors, including the specific agent administered and the underlying malignancy.Among patients with macular rash, vitiligo or multiple skin toxicities, patients received ICIs more frequently for melanoma than for non-small cell lung cancer.The combination of ICI and chemotherapy compared with ICI monotherapy occurred to a lesser extent in patients with psoriatic rash lichenoid and eczematous reactions, compared with patients with pruritus.Clinical awareness and specialized dermatological consultation should be advocated.

Published
2022
Full Text
View/download PDF

7. Topical immunotherapy treatment of alopecia areata with diphenylcyclopropenone: Regulatory T cells as biomarkers for treatment response

Author

Eirini Kyrmanidou, Zoi Apalla, Triantafyllia Koletsa, Eleni Sotiriou, Demetrios Ioannides, Christina Fotiadou, Stavros Chatzopoulos, Christina Kemanetzi, and Elisavet Lazaridou

Subjects
Cyclopropanes, Alopecia Areata, Humans, Immunologic Factors, Dermatology, General Medicine, Immunotherapy, T-Lymphocytes, Regulatory, Biomarkers
Abstract

Treatment of alopecia areata is often challenging, especially for patients with extended disease. Contact immunotherapy with diphenylcyclopropenone (DPCP) has been reported as an effective topical treatment but the exact immunologic mechanism of diverting the immune response is still unknown. We investigated the efficacy of topical immunotherapy with DPCD in acute, intermediate, and chronic lesions of AA and the response rate was associated with perifollicular infiltrate of T regulatory cells. Approximately two-thirds of our patients (67.5%) had a response rate 50% after 6 months of DPCP therapy. Patients with acute and intermediate onset of the disease were more likely to respond to the therapy. Although responders demonstrated FOXP3+ positive lymphocytes in immunohistochemistry, this association could not be confirmed by statistical significance (p = 0.052). In patients with multiple lesions, that had different chronological onset, the lesions with more recent onset responded faster than lesions of longer duration.

Published
2022

8. The impact of COVID-19 pandemic on psoriasis patients in northern Greece

Author

Elizabeth Lazaridou, Zoe Apalla, Aikaterini Patsatsi, Christina Trakatelli, Aimilios Lallas, Christina Fotiadou, Valentina Oflidou, Kalliopi Karydi, Athanassios Kyrgidis, Maria Boziou, Christina Kemanetzi, Styliani Siskou, Melpomeni-Maria Giannakaki, Athena Daponte, Eirini Kyrmanidou, Anastasia Trigoni, Fragkiski Tsatsou, Georgios Papazisis, Ourania Droggoula, Myrto Trakatelli, and Anastasia Emvalomati

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Greece, business.industry, SARS-CoV-2, COVID-19, Dermatology, General Medicine, medicine.disease, Vaccination, Family medicine, Psoriasis, Pandemic, medicine, Humans, business, Pandemics
Published
2021

9. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case

Author

Chryssoula Papageorgiou, Sofia Levva, Elizabeth Lazaridou, Zoe Apalla, Christina Fotiadou, Aimilios Lallas, Dimitrios Hatzibougias, Ioannis Boukovinas, Christina Kemanetzi, Eleni Stergiou, Mattheos Bobos, and Magdalini Manoli

Subjects
Male, medicine.medical_specialty, Skin Neoplasms, Sarcoidosis, medicine.medical_treatment, Ipilimumab, Dermatology, Pembrolizumab, Malignancy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Immune Checkpoint Inhibitors, Melanoma, business.industry, General Medicine, Immunotherapy, medicine.disease, 030220 oncology & carcinogenesis, Prednisolone, Female, Nivolumab, business, medicine.drug
Abstract

Sarcoidosis and sarcoid-like reactions (SLRs) may develop in association with various malignancies, as well as in association to certain oncologic drugs, including immune checkpoint inhibitors (ICIs). We aimed to perform a narrative review with regard to the development of ICIs-associated sarcoidosis or SLRs, and to discuss the corresponding diagnostic and therapeutic challenges raised in this scenario. Apropos of a melanoma patient developing SLRs while treated with ipilimumab and nivolumab, we searched for clinically evident, ICIs-associated sarcoidosis or SLRs in the English literature. We recorded the oncologic characteristics, including type of malignancy and type of ICI, the phenotypic characteristics of sarcoidosis/SLRs, as well as the impact on immunotherapy. Including our patient, we identified 80 ICIs-associated sarcoidosis or SLRs cases. Both sexes were equally affected (40 F/40 M) and the most common malignancy was melanoma (65/80, 81.3%). Concerning the oncologic treatment, there was a predilection for pembrolizumab (23/80, 28.7%), followed by the ipilimumab/nivolumab combination (21/80, 26.3%), ipilimumab (18/80, 22.5%), nivolumab (16/80, 20.0%). Although in the majority of the cases (52/80, 65.0%) there was no need for systemic prednisolone for the management of sarcoidosis, a significant proportion of patients finally discontinued ICIs treatment (44/80, 55.0%). Phenotypically, sarcoidosis and SLRs highly imitate oncologic progression posing diagnostic difficulties. A therapeutic dilemma is also raised when there is a need for systemic prednisolone, since the latter may jeopardize the therapeutic efficacy of immunotherapy. Sarcoidosis and SLRs, though rare, can present in oncologic patients treated with ICIs. Clinicians should be aware of this possibility and the related diagnostic and therapeutic challenges they have to face in this scenario.

Published
2020

10. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review

Author

Elizabeth Lazaridou, Zoe Apalla, Chryssoula Papageorgiou, Florentina Delli, Christina Fotiadou, Christina Kemanetzi, and Aimilios Lallas

Subjects
Ipilimumab, Pembrolizumab, Dermatology, Review, Bioinformatics, immune checkpoint inhibitors, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Immune system, Genetics, Medicine, ipilimumab, Adverse effect, Molecular Biology, nivolumab, business.industry, skin toxicity, Immune checkpoint, Blockade, Discontinuation, Oncology, 030220 oncology & carcinogenesis, RL1-803, adverse effects, pembrolizumab, Nivolumab, business, medicine.drug
Abstract

Immune checkpoint inhibitors (CPIs) are targeted molecules that modulate the immune system, assist with self-tolerance, and minimize collateral tissue damage when immune responses are activated. Although they are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-like toxicities, named immune-related adverse events (irAE). Dermatologic reactions are among the most prevalent irAE triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients’ quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs.

Published
2020

11. Rosacea and Helicobacter pylori: links and risks

Author

Efstratios Vakirlis, Demetrios Ioannides, Aimilios Lallas, Elena Sotiriou, Christina Kemanetzi, Chrysovalantis Korfitis, Elizabeth Lazaridou, Christina Fotiadou, and Zoe Apalla

Subjects
medicine.medical_specialty, biology, business.industry, Dermatology, Helicobacter pylori, medicine.disease, biology.organism_classification, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Rosacea, Etiology, Medicine, Chronic skin disease, 030211 gastroenterology & hepatology, Clinical significance, Facial erythema, business
Abstract

Rosacea is a chronic skin disease characterized by facial erythema and telangiectasia. Despite the fact that many hypotheses have been proposed, its etiology remains unknown. In the present review, the possible link and clinical significance of Helicobacter pylori in the pathogenesis of rosacea are being sought. A PubMed and Google Scholar search was performed using the terms "rosacea", "H.pylori", "gastrointestinal disorders and H.pylori", "microorganisms and rosacea", "pathogenesis and treatment of rosacea", and "risk factors of rosacea", and selected publications were studied and referenced in text. Although a possible pathogenetic link between H. pylori and rosacea is advocated by many authors, evidence is still interpreted differently by others. We conclude that further studies are needed in order to fully elucidate the pathogenesis of rosacea.

Published
2017
Full Text
View/download PDF

12. Artificial neural networks and statistical classification applied to Electrical Impedance Spectroscopy data for Melanoma diagnosis in Dermatology (DermaSense)

Author

Panagiotis D. Bamidis, Sotiria Gilou, Alexandros Astaras, A. Zogkas, Elizabeth Lazaridou, C. Dimitrousis, Christina Kemanetzi, and Chrysovalantis Korfitis

Subjects
Statistical classification, medicine.medical_specialty, Artificial neural network, business.industry, Cutaneous melanoma, Pattern recognition (psychology), Medicine, Gold standard (test), Electrical impedance spectroscopy, business, Melanoma diagnosis, Dermatology, Histological examination
Abstract

The gold standard for diagnosis of cutaneous melanoma is excisional biopsy and histological examination, however dermoscopy remains the most common examination during a patient’s first visit to the dermatologist. Dermoscopy is non-invasive but relies on a clinician’s subjective pattern recognition skills and experience. We designed and built a novel, non-invasive dermatological scanner based on electrical impedance spectroscopy, which can complement dermoscopy by providing objective measurement data within seconds, at the point-of-examination. In this paper we present the DermaSense scanner as well as associated statistical and neural network classification algorithms aimed at correlating acquired with verified diagnostic data. In addition, we present an initial pilot study on measurements of melanoma against nevi as well as against clear patches of skin.

Published
2018
Full Text
View/download PDF

13. Abstracts from the 4th World Congress of the International Dermoscopy Society, April 16-18, 2015, Vienna, Austria

Author

Michael A. Marchetti, Alexandros Stratigos, Claudia Jaeger, Nanja van Geel, Erika Varga, Rachel M Bowden, Nebojsa Pesic, Lauren A. Penn, Francesca Farnetani, Irena Walecka, Otto S. Wolfbeis, Anna Pogorzelska-Antkowiak, Małgorzata Zadurska, Miriam A. Jesús Silva, Mari Grönroos, Fabrizio Ayala, Claudia Sprincenatu, Ausilia Maria Manganoni, Jhonatan Rafael S. Pinheiro, Vincent Descamps, Era C. Murzaku, Josephine Rau, Christian Landi, Josep Malvehy, Othon Papadopoulos, Renato Talamini, Savitha L. Beergouder, Adrian Ballano Ruiz, Karina Scandura, Flavia Persechino, Yunxian Tian, Mark Berneburg, Iara Drakensjö, Luis Javier Del pozo, Elizabeth Lazaridou, Marwah A. Saleh, Wei Zhang, Dalal Mosaad, Aida Carolina Medina, Alka Lalji, Robabeh Abedini, FZ Debagh, Ligia Brzezinska-Wcislo, Nurşah Doğan, Naglaa Ahmed, Tamerlan Shaipov, Ritta Khoury, Lidija Kandolf-Sekulovic, Aldo Bono, Luis Angel Vera, Naotomo Kambe, Jaka Rados, Sergio Talarico, Milvia Maria S. E. S. Enokihara, Iris Zalaudek, Malgorzata Maj, Francesca Specchio, Paloma Arribas, Nazan Emiroglu, Andreea Ioana Popescu, Irina Sergeeva, Virginia Chitu, Michael Kirschbaum, Sergio Yamada, Niken Wulandari, Rotaru Maria, Lore Pil, Lieve Brochez, Anthony Azzi, Vasiliy Y. Sergeev, Raimonds Karls, Zeynep Topkarci, Tanja Planinsek Rucigaj, Osvania Maris, Graham J. Mann, Timótio Dorn, Lubomir Drlik, Pilar Iranzo, Sara Minghetti, Michael Noe, Ahmet R Akar, Jesus Cuevas Santos, Laura Raducu, Salim Ysmail-Dahlouk, Laura Mazzoni, Sidharth Sonthalia, Neşe Çallı Demirkan, Yaei Togawa, Branislava Gajic, Ayelet Rishpon, Chih-Hsun Yang, Barbara Boone, José Luis López-Estebaranz, Markus Albert, George Evangelou, André L.M. Oliveira, Ioana Gencia, Nada Vuckovic, Rosa Perelló, Ana Maria Draganita, Michel Colomb, Ayse Cefle, Hongguang Lu, Annarosa Virgili, Hayriye Saricaoglu, Esther A.W. Wolberink, Michael Russu, Elisabeth Arnoult-Coudoux, Caroline Nicaise-Bergère, Aleksandra M Ignjatović, Necmettin Özdemir, Kristīne Zabludovska, Cemal Bilaç, Jose Luis Lopez Estebaranz, Marie-Christine Lami, Harold S. Rabinovitz, Izabel Bota, Damien Grivet, Dimitrije Brasanac, Andrei Jalba, Joep Hoevenaars, Sofie De Schepper, Deniz Duman, Vladimir Vasku, Anna Belloni Fortina, Rosa Cristina Coppola, Marion Chavez-Bourgeois, Hoon-Soo Kim, Zamira Barragan, Julia Welzel, Thomas Ruzicka, Patricia V. Cristodor, Pierfrancesco Zampieri, Michael Lanthaler, Marc Haspeslagh, Jürgen Christian Becker, Gamze Erfan, Tanja Maier, Hui Mei Cheng, Mauro Enokihara, Ana Arance, Emel Dikicioglu Cetin, Pranaya A. Bagde, Mona M. Elfangary, Stefano Cavicchini, Alicia Barreiro, Odivânia Krüger, Mariana Petaccia Macedo, Itziar Erana Tomas, Elimar Elias Gomes, Monika Vrablova, Marcio Lorencini, Javier Alcántara González, Giuseppe Micali, Kerstin Kellermann, Mauricio Mendonca do Nascimento, Elisabeth Mt Wurm, Elena Sánchez-Largo Uceda, Yury Sergeev, Céleste Lebbé, Manfred Fiebiger, Gisele Gargantini Rezze, Antonio Graziano, Ana Pampín, Márcia Ferreira Candido, Martine Bagot, Jan Lapins, Nahide Onsun, Daniela Göppner, Katie Lee, Josef Schröder, Gisele G Rezze, Reyes Gamo, Mauricio Soto-Gamboa, Giovanni Pellacani, Maria Luiza P. Freitas, Mizuki Sawada, Hyun-Chang Ko, Ramon M Pujol Vallverdú, Jin gyoon Park, Peter Weber, Alberto Mota, Theofanis Spiliopoulos, Renata B. Marques, Daiji Furusho, Barbora Divisova, Pascale Guitera, Johan Heilborn, Alexandr Fedoseev, Athanasios Kyrgidis, Zakia Douhi, Mariame Meziane, Florent Grange, Alister Lilleyman, Juliana C. Marques-Da-Costa, Mitsuyasu Nakajima, Camilla Reggiani, Marina Meneses, Anna Sokolova, Zoe Apalla, Leo Čabrijan, Tim Lee, Piergiacomo Calzavara-Pinton, Tomas Fikrle, Georgios Chaidemenos, Braun Ralph, Aikaterini Patsatsi, Ekin Şavk, Marcela Pecora Cohen, Ioannis Efstratiou, Gurol Acikgoz, Pietro Quaglino, Nati Angelica, Luc Thomas, Edileia Bagatin, Kedima C. Nassif, Dimitrios Sotiriadis, Regina Fink-Puches, Anna Maria Wozniak, Salvador González, Agnieszka Buszko, Fezal Ozdemir, Banu Yaman, Vishnu Moodalgiri, Anne Grange, Robert J Meier, Davorin Loncaric, Fatmagül Keleş, Renato Marchiori Bakos, Sergio Chimenti, Sebastian Podlipnik, Pınar Incel Uysal, Devinder M Thappa, Nida Kaçar, Emel Bulbul Baskan, Erna Snellman, Pietro Rubegni, J. Kreusch, Hae Jin Pak, Danijela Dobrosavljevic Vukojevic, Bengü Nisa Akay, Holger A. Haenssle, Horacio Cabo, Anna Rammlmair, Fred Godtliebsen, Chiara Ferrari, Hiroshi Sakai, Christina Kemanetzi, Åsa Ingvar, Jitka Suchmannova, Zlata Janjic, Samira Zobiri, Haishan Zeng, Emine Böyük, Antonello Felli, Je-Ho Mun, Pablo Fernández Peñas, Ercan Caliskan, Satish S. Udare, Borna Pavičić, Max Hundeiker, Cristel Ruini, A. Hakan Cermik, Ülker Gül, Auro ra Parodi, Timothy P. Wu, Bernardo Gontijo, Ivan Klyuzhin, Gabriela Turcu, Sylvia Aidé Martínez-Cabriales, Francisco Alcántara Nicolás, Inge A. Krisanti, Sandra Cecilia García-García, Meriem Benfodda, Nika Madjlessi, Paraskevi Karagianni, Gizem Yağcıoğlu, Didem Dizman, Danielle I. Shitara, Nilda Eliana Gomez-Bernal, Mirna Šitum, Natalia Ilina, Job Van Der Heijden, Małgorzata Kwiatkowska, Bota Izabel, Ismini Vassilaki, Irene Potouridou, Jorge Luis Rosado, Lukas Prantl, María-José Bañuls, Fernando N. Barbosa, Seitaro Nakagawa, Jana Dornheim, Hitoshi Iyatomi, Rifat Saitburkhanov, Çiğdem Çağlayan, Natalie Ong, Stefano Gardini, Temeida Alendar, Zrinka Rendić-Miočević, Ryuhei Okuyama, Wafae Bono, Olga Warszawik-Hendzel, Danica Tiodorovic-Zivkovic, Alise Balcere, Ramazan Kahveci, Sebastian Gehmert, Herbert M. Kirchesch, Fernando Javier Pinedo, Raul Niin, Dan Savastru, Andreas Blum, Valeria Coco, Alexander C. Katoulis, Yosuke Yamamoto, Mumtaz Jabeen, Louise De Brot Andrade, Lidia Rudnicka, Pierre Wolkenstein, Fatma Pelin Cengiz, Woo-il Kim, Rainer Hofmann-Wellenhof, Tine Vestergaard, Maria Valeria B. Pinheiro, Ana Filipa Pedrosa, Caroline M. Takigami, Nilgün Bilen, Feroze Kaliyadan, Lotte Themstrup, Awatef Kelati, Katrien Vossaert, Burak Sezen, Natalia Jaimes, Olga Zhukova, Peter Jung, Nidhi Singh, Uxua Floristan, Ivette Alarcon, Michel Baccard, Flávia V. Bittencourt, Nicolas Dupin, Neslihan Şendur, Flavia Boff, Lydia Garcia Gaba, João Pedreira Duprat Neto, Caius Solovan, Byung Soo Kim, Anamaria Jović, Toshitsugu Sato, Antoni Bennassar, Ilkka Pölönen, Svetlana Rogozarski, Agnieszka Kardynał, Harald P.M. Gollnick, Anastasia Trigoni, Harvey Lui, Hiroshi Koga, Dai Ogata, Zeynep N. Saraçoğlu, Nilton B Rodrigues, Ketty Peris, Vanessa da Silva, Akira Hamada, Monica Corazza, Azmat A. Khan, Cengizhan Erdem, Victor Desmond Mandel, Sabina Zurac, Laura Elena Barbosa-Moreno, Filomena Azevedo, Matsue Hiroyuki, Philippe Saiag, Kara Shah, Stephen W. Dusza, Margaret Song, Francesca Giusti, Lidija Zolotarevski, Romain Vie, Rutao Cui, Aylin Okçu Heper, Kerstin Wöltje, Kyoko Tonomura, Charlotte H. Vuong, Moira Ragazzi, Marta Andreu Barasoain, Stephan Schreml, Branka Marinović, Mona R E Abdel Halim, Selimir Kovacevic, Noriaki Kamada, Adriana Garcia-Herrera, Ayse S. Filiz, Helena Collgros, Joan A. Puig-Butille, Ulvi Loite, Meng-Tsan Tsai, Nele Degryse, Philipp Tschandl, Seiichiro Wakabayashi, Korina Tzima, Kari Nielsen, Edith Arzberger, Alain Archimbaud, Makiko Miyamoto, Steffen Emmert, Katharine Hanlon, Stefano Astorino, Andre Sobiecki, Trevino A Pakasi, Giovanni Ghigliotti, Arzu Karataş Toğral, Sara Bassoli, Mahdi Akhbardeh, Martina Ulrich, Mirna Bradamante, Gökhan Uslu, Ross Flewell-Smith, Mauro Alaibac, Bettina Kranzelbinder, Steven Gazal, Nina Malishevskaya, Mikhail Ustinov, Noora Neittaanmäki-Perttu, Olga Simionescu, Saime Irkoren, Mahsa Ansari, Mustafa Turhan Sahin, Priit Kruus, Jana Janovska, Vesna Gajanin, Giovanni Ponti, Alon Scope, Ozkan Kanat, Cesare Massone, Thomas Schopf, Karolina Hadasik, Magnus Karlsson, Ayça Tan, Ignacio Gómez Martín, Armand Bensussan, Dilara Tüysüz, Saleh M. H. El Shiemy, Ine De Wispelaere, Malou Peppelman, Kenan Aydogan, Christian Teutsch, Ryszard A. Antkowiak, Nathalie De Carvahlo, Fatma Shabaka, Matthias Karasek, Christina Fotiadou, Wael M. Saudi, Matthias Weber, Maria Saletta Palumbo, Elisa Benati, Hana Helppikangas, Mariana Grigore, Leonard Witkamp, Rajiv Kumar, Stella Atkins, Eugene Y. Neretin, Dirk Berndt, Piet E.J van Erp, Alessandro Testori, David Duffy, Steluta Ratiu, Tara Bronsnick, Christoph Rinner, Soo-Han Woo, Federica Ferrari, Gabriela Garbin, Eduardo Nagore, Claus Duschl, Caterina Longo, Daniel Alcala-Perez, Helmut Beltraminelli, Sarah Hedtrich, David C McLean, Bojana Spasic, Martin Laimer, Malgorzata Pawlowska-Kisiel, Bohdan Lytvynenko, Heba I. Nagy Abd El-Gawad, Jean-Luc Perrot, Daška Štulhofer Buzina, Dimitrios Rigopoulos, Christian Hallermann, Jeffrey Keir, Adriana Martín Fuentes, Franz Trautinger, Walter L. G. Machado, Emese Gellén, Tatjana Ros, Gabriella Emri, Pinar Y. Basak, Nilay Duman, Reinhart Speeckaert, Peter Komericki, Maciel Zortea, Raphaela Kaestle, Lucía Pérez Carmona, Masaru Tanaka, Ionela Manole, Calin Giurcaneanu, Cristina Carrera, Jianhua Zhao, Marsha Mitchum, Isil Kilinc Karaarslan, Michael Muntifering, Alice Casari, Nicole Basset-Seguin, Seok-Kweon Yun, Vesna Mikulic, Albert Brugués, Kim-Dung Nguyen, Reshmi Madankumar, Joo-Ik Kim, Anna Skrok, Nicolle Mazzotti, Aomar Ammar-Khodja, Alina Avram, Laxmisha Chandrashekar, Dilek Biyik Ozkaya, Refika F. Artuz, Joanna Czuwara-Ladykowska, Hana Szakos, Dejan M Nikolic, Katarzyna Żórawicz, Georg Duftschmid, Natalia Pikelgaupt, Jorge Ocampo-Candiani, Irdina Drljevic, Canten Tataroglu, Esther Jiménez Blázquez, Philippe Gain, Simonetta Piana, Yunus Bulgu, Lars Dornheim, Bruno Labeille, Helmut Schaider, Nitul Khiroya, Sofia Theotokoglou, Christian Morsczeck, Kalliopi Armyra, Serap Öztürkcan, Shricharit h Shetty, Ozlem Su, Susana Puig, Lina Ivert, Katia Ongenae, Hirotsugu Shirabe, Ardalan Benam, Gustav Christensen, Veronika Paťavová, Adria Gual, Laura Pavoni, Mihaita Viorica Mihalceanu, Slobodan Jesic, Abdurrahman Bugra Cengiz, Jerome Becquart, Yasutomo Mikoshiba, Mattia Carbotti, Marcelo O. Samolé, Margherita Raucci, Sven Lanssens, Maria João M. Vasconcelos, Valeriy Semisazhenov, Fabio Facchetti, Monia Maccaferri, Vincenzo Panasiti, Camila M. Carvalho, Elena Tolomio, Ercan Arca, Celia Badenas, Sonia Segura Tigell, Francesco Lacarrubba, Ruzica Jurakic Toncic, Uday Khopkar, Uwe Seidl, Clóvis Antônio Lopes Pinto, Alice Marneffe, Zhenguo Wu, Josefin Lysell, Malgorzata Olszewska, Marta Ruano Del Salado, Alina Gogulescu, Tarl W. Prow, Christine Fink, Jean-Marie Tan, Milana Ivkov Simic, Mahshid S. Ansari, Stamatina Geleki, Sondang P. Sirait, Flavia Baderca, Marcella N. Silva, Andra Pehoiu, Joost Koehoorn, Ajay Goyal, Maria Dirlei Ferreira de Souza Begnami, Hui-bin Lu, Hoda A. Moneib, Maria Antonietta Pizzichetta, Scott Menzies, Gulsel Anil Bahali, Vesna Tlaker Zunter, Elfrida Carstea, Ines Chevolet, Septimiu Enache, Aysun Şikar Aktürk, Clara Kirchner, Greg Canning, Dina M. Shahin, Incilay Kalay Tugrul, Kristina Opletalova, Lars Hofmann, Mario Santinami, Anna Elisa Verzì, Asunción Vicente, Nathalia Delcourt, null Mernissi, Duru Tabanlıoglu Onan, Dorothy Polydorou, Irma Korom, Sara Moreno Fernández, Salim Gallouj, Annamari Ranki, Riina Hallik, Saduman Balaban Adim, Erietta Christofidou, Gustavo D. C. Dieamant, Vincenzo De Giorgi, Gregor B.E. Jemec, Kajsa Møllersen, Monisha lalji, Georgiana Simona Mohor, Hans-Jürgen Schulz, Justin R Sharpe, Karinna S. Machado, Efterpi Demiri, Mohammed I. AlJasser, Jelena Stojkovic-Filipovic, Harald Kittler, José M. A. Lopes, Adriana Diaconeasa, Patricia Serrano, Alfonso D’Orazio, Luca Mazzucchelli, Riccardo Bono, Oliver Felthaus, Juan Garcias-Ladaria, Zeljko Mijuskovic, Zsuzsanna Bago-Horvath, Alin Laurentiu Tatu, Christine Prodinger, Roland Blum, Demetrios Ioannides, Nadem Soufir, Diego Serraino, Ahmed M. Sadek, Leticia Calzado Villareal, Elliot Coates, Mariana Costache, Machuel Bruno, Bengu Gerceker Turk, Liliana Gabriela Popa, Han-Uk Kim, Lisa Hoogedoorn, Efstratios Vakirlis, Monika Kotrlá, Gabriel Salerni, Ela Comert, Salvatore Zanframundo, Zsuzsanna Lengyel, Francisco Jose Deleon, Maryam Sadeghi Naeeni, Georgios Kontochristopoulos, Ana Carolina Cherobin, Michiyo Matsumoto-Nakano, Gabriela Fortes Escobar, Maria Concetta Fargnoli, Ayse Oktem, Petra Fedorcova, Slavomir Urbancek, Hyunju Jin, Frédéric Cambazard, Tracey Newlove, Nataliya Sirmays, Cliff Rosendahl, Tamara Micantonio, Shirin Bajaj, Masa Gorsic, Ana Carolina L. Viana, Valentin Popa, Hubert Pehamberger, Anna Maria Carrozzo, Valentina Girgenti, Phil McClenahan, Beata Bergler-Czop, Alex Llambrich, Özgür Bakar, David Polsky, Krishnakant B. Pandya, Andrea Maurichi, Isabelle Hoorens, Paola Sorgi, Marianne Niin, Serena Magi, Malathi Munisamy, Zlatko Marušić, Cristina Mangas, Hakan Yesil, Miriam Potrony, Safaa Y. Negm, Maria T. Corradin, Stefania Seidenari, Işıl Bulur, Evelin Csernus, Gemma Tell-Marti, Alix Thomas, Juliana Casagrande Tavoloni Braga, Marco Manfredini, Karime M. Hassun, Celia Levy-Silbon, Lali Mekokishvili, Cem Yildirim, Hanna Eriksson, John H. Pyne, Angel Pizarro, Hakim Hammadi, Alessandro Borghi, Mariana A. Cordeiro, Fatima Zohra, A. Tülin Güleç, Ivan Ruiz Victoria, Joanna N. Łudzik, Radwa Magdy, Hisashi Uhara, Grażyna Kamińska-Winciorek, Llúcia Alòs, Pegah Kharazmi, Keisuke Suehiro, Lucian Russu, Zorica Đorđević Brlek, Sandrine Massart-Manil Massart-Manil, Moon-Bum Kim, Noha E. Hashem, Domenico Piccolo, Francesca Cicero, Jan Szymszal, Verena Ahlgrimm-Siess, Marian Gonzalez Inchaurraga, Ignazio Stanganelli, Danica Tiodorovic Zivkovic, Bugce Topukcu, Katharina Jaeger, Michael J. Inskip, Sara M. Mohy, Assya Djeridane, Véronique Del Marmol, Isil Kilinc, Nehal Yossif, Geon-Wook Kim, Oleksandr Litus, Ivana Ilić, Richard A Sturm, Mustafa Tunca, Anndressa da Matta, Elisabeth Jecel, Danijela Ćurković, Giuseppe Argenziano, Lynlee L. Lin, Elena Sotiriou, Mikela Petkovic, Suzana Kamberova, Sara Ibañes del Agua, Alan Cameron, Judit Oláh, Marc Nahuys, Leila Jeskanen, Zrinjka Paštar, Anna Wojas-Pelc, Ingela Ahnlide, Romana Čeović, Geoffrey Cains, Gilles Thuret, Mary Thomas, Marios Fragoulis, Drahomira Jarosikova, Manfred Beleut, Ferda Artüz, Brigitte Lavole, Francesco Todisco Grande, Carine Dal Pizzol, Erika Richtig, Nathalie Teixeira De Carvalho, Hans Peter Soyer, Amer M Alanazi, Vesna Sossi, Manal Bosseila, Monica Sulitan, Biancamaria Scoppio, Zrinka Bukvić Mokos, Marie-Jeanne P. Gerritsen, Mariano Suppa, Danielle Giambrone, Christoph Sinz, Jernej Kukovic, Martina Bosic, Adriana Rakowska, Eleni Mitsiou, Kely Hernandez, Ashfaq A. Marghoob, Daniel Boda, Alessandro Di Stefani, Luciana Trane, Leo Raudonikis, Akane Minagawa, Itaru Dekio, Athanassios Kyrgidis, Magdalena Wawrzynkiewicz, Katharina T Weiß, Chie Kamada, Lamberto Zara, Cristian Navarrete-Dechent, Serkan Yazici, Frédéric Renard, Leonie Mathemeier, Nissrine Amraoui, Mariana Fabris, Mariola Wyględowska-Kania, Nikolay Potekaev, Elisa Cinotti, Sedef Şahin, Peter van de Kerkhof, Silvana Ciardo, Sara Izzi, Paolo Piemonte, William V. Stoecker, Giampiero Mazzocchetti, Pasquale Frascione, Louise Lovatto, Ayşegül Yalçınkaya Iyidal, Jennifer A. Stein, Selçuk Yüksel, Daniela Ledić Drvar, Stine F. Pedersen, Dimitrios Sgouros, Meriem Bounouar, Balachandra S Ankad, Rahul Bute, Julia Brockley, Paula Aguilera-Otalvaro, Sumiko Ishizaki, Daniela Kulichova, Ilias Papadimitriou, Yeser Genc, Tanja Batinac, Jadran Bandic, Jean-Michel Lagarde, Göksun Karaman, Philipp Babilas, Mari Salmivuori, Lieven Annemans, Lennart K Blomqvist, Karel Pizinger, Duncan Lambie, Alexander Michael Witkowski, Meltem Uslu, Irena Savo, Martin Gosau, Raphaela Kastle, Olli Saksela, Pedro Zaballos, Esther De Eusebio Murillo, Hu Hui-Han, Sanda Mirela Cherciu, Claudia Artenie, Elvira Moscarella, Richard Johns, Ozlem Erdem, Valérie Vuong, Basma Birqdar, Jela Tomkova, Kasturee Jagirdar, Vassilios Lambropoulos, Moshira S. Bahrawy, Seong-Jin Kim, Su Chii Kong, Helen Schmid, Tetsuya Tsuchida, Michele Tonellato, Laura Berbegal, Lumír Pock, Iustin Hancu, Babar K Rao, Juliette Jegou, Lajos Kemény, Teresa Deinlein, Usha N. Khemani, Davive Guardoli, Juliana Arêas de Souza Lima Beltrame Ferreira, Tatiana Cristina Moraes Pinto Blumetti, Adhimukti T. Sampurna, Alexandru Telea, Ana Maria Forsea, Gionata Marazza, Lidija Kandolf Sekulovic, Marta Kurzeja, Marija Buljan, Fatima Zohra Mernissi, Alba Maiques-Diaz, Roger González, Dimitrios Kalabalikis, María Gabriela Vallone, Vanessa P. Martins Da Silva, Gemma Flores-Pons, Giuseppe Bertollo, Rolland Gyulai, Giuliana Crisman, Secil Saral, Simon Nicholson, Aimilios Lallas, Willeke Blokx, Marc A. L. M. Boone, and Oana Sindea

Subjects
Oncology, business.industry, RL1-803, Genetics, Medicine, Library science, Environmental ethics, Dermatology, business, Molecular Biology
Published
2015
Full Text
View/download PDF

14. Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center

Author

Christina Fotiadou, Demetris Ioannides, Elizabeth Lazaridou, Eirini Kyrmanidou, and Christina Kemanetzi

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, Injections, Subcutaneous, Arthritis, Dermatology, Severity of Illness Index, Drug Administration Schedule, Sampling Studies, Uveitis, Psoriatic arthritis, Psoriasis, Severity of illness, medicine, Adalimumab, Humans, Referral and Consultation, Retrospective Studies, Dose-Response Relationship, Drug, Tumor Necrosis Factor-alpha, business.industry, Antibodies, Monoclonal, Retrospective cohort study, Middle Aged, medicine.disease, Treatment Outcome, Immunology, Female, Tumor necrosis factor alpha, business, Follow-Up Studies, medicine.drug
Abstract

Background The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7–20%. The use of tumor necrosis factor-α (TNF-α) inhibitors as a treatment for refractory uveitis is emerging. Methods The psoriasis outpatient database at our referral center was searched for patients with concurrent diagnoses of psoriasis and uveitis. The medical records of the patients identified were reviewed for the use of TNF-α inhibitors. Results Five patients (three women and two men) were identified. All of them suffered moderate to severe psoriasis and chronic, bilateral uveitis. The patient with the most severe ocular inflammation was the only patient positive for human leukocyte antigen B27 (HLA-B27) and the only one to suffer from psoriatic arthritis. All patients had received treatment with adalimumab and had been evaluated at three and six months. Their psoriasis had responded excellently, and in four patients, uveitis had shown the complete remission of inflammation at six months. The fifth patient (HLA-B27+) exhibited improved uveitis activity but not complete remission at six months. Conclusions Uveitis is an entity that should be considered when evaluating psoriasis patients with ocular complaints, even in the absence of arthritis. Anti-TNF-α monoclonal antibodies and adalimumab in particular seem to represent a promising therapeutic avenue for the treatment of refractory psoriatic uveitis. Larger randomized clinical trials are needed to confirm our conclusions.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results